All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...
Zacks.com on MSN1d
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...
AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...
The move comes as the company faces ‘several challenges’ around the launching of medicines and timed out patents ...
UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...
The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.
AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario ’s growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback